India's Sun Pharmaceutical intends to be the white knight that will turn around manufacturing problems at Ranbaxy Laboratories once it finalizes its $3.2 billion buyout of the troubled drugmaker. But a warning letter posted today by the FDA says employees at a now-banned Sun Pharmaceutical plant in India displayed the same kind of disregard for data testing that Ranbaxy has, deleting records of failed samples and then retesting products till it got the results it needed. Some batches that fell out of spec ended up being shipped to the U.S., while some test results were put in the trash, the FDA said. Story | More